Report

The Pharmaceutical Manufacturing Software Market is expected to register a CAGR of 7.7 % during the forecast period (2022-2027).

Covid-19 has significantly impacted the market growth due to the rise in the need for dependence on Automation and reducing human capital. For instance, according to the study published in the International Journal of Pharmaceutics, titled 'Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future in May 2021, the COVID-19 public health emergency has brought attention to the need for manufacturing technologies that can adapt to shifting demand and reduce reliance on human involvement.

The major factors driving the growth of market growth include the rise in the adoption of pharmaceutical manufacturing software by pharmaceutical companies, the increasing cost of drug manufacturing, the increase in industrial Automation, and the increasing need to address manual errors, among others. The rise in the launch of pharmaceutical manufacturing software in the market will lead to increased adoption of such software by the pharmaceutical companies, driving the market growth. For instance, in January 2022, Aizon launched its new asset monitoring application for pharmaceutical manufacturers and biotech companies. Built on Aizon's GxP compliant AI SaaS Platform, Aizon Asset Health provides intelligent historical maintenance analysis, proactively monitors the condition of critical assets in real-time, identifies potential problems, and provides actionable maintenance recommendations that keep equipment up and running optimally.

According to the article published by the European Federation of Pharmaceutical Industries and Associations in 2021, pharmaceutical production in Europe is valued at EUR 293,213 million in 2019 and is estimated to be EUR 310,000 in 2020. Such a high rise in investments in the pharmaceutical industry will lead to the rising adoption of pharmaceutical manufacturing software, driving the market's growth.

In addition, according to the article published in Pharmabiz, titled 'Automation in the pharmaceutical industry in December 2021, increased Automation can help the pharmaceutical business use energy and raw materials more efficiently, increase worker safety, improve regulatory compliance, and improve product quality and consistency. Such studies will therefore lead to a rise in the adoption of pharmaceutical manufacturing software to achieve better quality and productivity in pharmaceutical manufacturing, thereby driving the market's growth. However, the high cost of pharmaceutical manufacturing software, security concerns about on-cloud deployment, and other factors are expected to hamper the market growth.

Pharmaceutical Manufacturing Software Market Trends

On-Cloud Software is Expected to Hold a Significant Share in the Market Studied

On-Cloud Software is expected to hold a significant market share in pharmaceutical manufacturing software. Most drug manufacturing initiatives involve budgets and resources that fluctuate. Pharma firms use cloud Enterprise resource planning (ERP) solutions to easily scale up and down resources and team strengths based on the specific needs of a project. Such technologies also make it easier for businesses to accelerate their go-to-market plans and expand into new markets.

The rise in collaborations among pharmaceutical manufacturing companies and healthcare software manufacturers to develop on-cloud software for pharmaceutical manufacturing will drive market growth during the forecast period. For instance, in May 2021, Mankind Pharma partnered with Accenture to drive its digital transformation with a data-driven cloud platform, the path toward becoming an intelligent enterprise, resulting in increased business agility, performance, and operational efficiency. Accenture revamped the pharma giant's business processes in critical areas like finance, supply chain, sales, and procurement to improve inventory management, demand planning, labor productivity, and product availability.

In addition, according to the news published in April 2021, advancements in the Internet of Things (IoT) space, such as the deployment of fifth-generation (5G) wireless infrastructure and cloud edge computing solutions, will enable the creation of automated manufacturing processes and, eventually, new business models in the pharmaceutical industry. Such advancements will further lead to the adoption of on-cloud software, driving the segment's growth. Therefore, owing to the abovementioned factors, this segment is expected to drive significantly over the forecast period.

North America Holds Significant Market Share and Expected to do the Same Over the Forecast Period

North America holds a major share in the pharmaceutical manufacturing software market, and it is expected to do the same over the forecast period. The factors responsible for the growth of this market in North America include the developed healthcare system, the rise in pharmaceutical production, the rise in the launch of pharmaceutical manufacturing software in the region, the sophisticated healthcare infrastructure, and the strong foothold of key market players, among others.

For instance, in December 2021, Amazon Web Services (AWS), Inc. collaborated with Pfizer to develop innovative cloud-based solutions that could revolutionize how new medications are created, manufactured, and disseminated for clinical trials. Pfizer's Amazon Collaboration Team (PACT) program uses AWS capabilities in analytics, machine learning, computation, storage, security, and cloud data warehousing to Pfizer's laboratory, clinical manufacturing, and clinical supply chain operations is investigating these advancements. Collaboration of manufacturing software providers with large enterprises such as Pfizer will drive the market growth in this region.

In addition, in April 2022, Optimal Industrial Automation and Technologies, a provider of pharma and biopharma process analytical technology (PAT), pharma factory automation, and Quality Assurance (QA) software and systems integration, was acquired by Bruker Corporation. Bruker's position as a prominent software and solutions provider for small molecule, biologics, and new drug modalities pharma businesses is strengthened by the acquisition of Optimal biopharma tools.

Furthermore, in September 2021, Honeywell purchased Performix Inc., a privately held developer of manufacturing execution system (MES) software for the pharmaceutical and biotech industries. Honeywell's ambition to create the world's top integrated software platform for customers in the life sciences industry who want to achieve speedier compliance is being strengthened by this acquisition. Such an increase in acquisitions will lead to a rise in software adoption by other pharmaceutical companies to adopt automation and increase the speed of the production process, driving the market growth in this region. Therefore, the market is expected to drive in North America due to the abovementioned factors.

Pharmaceutical Manufacturing Software Market Competitor Analysis

The market for pharmaceutical manufacturing software is moderately competitive. The market is driven by the factors such as the rise in automation in the pharmaceutical industry, the need to reduce manual errors, the rise in the launch of innovative software by the key market players, and the increasing partnerships among pharmaceutical companies and software providers, among others. Some key market players include BatchMaster Software, MasterControl, Inc, Vormittag Associates, Inc., Oracle, and Fishbowl.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support